Shandong Wohua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 28, 2021 at 05:19 am
Share
Shandong Wohua Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 711.07 million compared to CNY 750.51 million a year ago. Revenue was CNY 711.07 million compared to CNY 750.51 million a year ago. Net income was CNY 136.88 million compared to CNY 140.76 million a year ago. Basic earnings per share from continuing operations was CNY 0.24 compared to CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.24 compared to CNY 0.24 a year ago.
Shandong Wohua Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of Chinese traditional patent medicines. The Company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Gushu tablets for the treatment of middle-aged and senile osteoporosis, and Hedan tablets for promoting blood circulation and for the treatment of hyperlipidemia. The Company distributes its products in domestic market, mainly in East China, North China and Northeast China.